Drug Trial Radar · NCT00618436
Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention
Last checked: Nov 20, 2026Latest source record: Apr 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Aug 2007
Primary completion
Sep 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- University of CincinnatiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mayfield Clinic & Spine Institute
- First posted
- Feb 20, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To show that the use of intravenous levetiracetam(LEV;Keppra)for seizure prevention in patients in the Neuroscience Intensive Care Unit will result in fewer side effects compared to the current standard of care anticonvulsant and will be at least as effective as the current standard of care in preventing clinical and sub-clinical seizure activity.
Conditions
- Traumatic Brain Injury
- Subarachnoid Hemorrhage
Interventions
LevetiracetamDrug
Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
PhenytoinDrug
The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seizure IncidenceTime frame: Duration of study, up to 6 months after the injury
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Cincinnati Hospital
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.